{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T02:25:00Z","timestamp":1697163900937},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Patients with cancer receiving pregabalin potentially have a high incidence of central nervous system (CNS) symptoms. The purpose of this study was to explore clinical factors influencing the incidence of CNS symptoms, including plasma pregabalin exposure, cancer cachexia, and opioid analgesic cotreatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Sixty-eight patients with cancer receiving twice-daily pregabalin were enrolled. Plasma concentrations of pregabalin, clinical laboratory data, opioid analgesic cotreatment, and the Glasgow Prognostic Score, which is an inflammation-based cachexia score, were considered as clinical factors. The incidence of CNS symptoms was collected from the patients' medical records. The predose plasma concentrations of pregabalin at steady state were determined by ultra-high-performance liquid chromatography.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The steady-state trough plasma pregabalin concentrations showed a large variability with an interquartile range of 0.43\u20131.2 mg\/L per mg\/kg and were negatively correlated with an estimated glomerular filtration rate (eGFR). C-reactive protein (standardized partial regression coefficient, \u03b2 = 0.31) and opioid analgesic cotreatment (\u03b2 = 0.24) were also identified in addition to eGFR (\u03b2 = \u22120.60) in the multiple regression analysis. The incidence of CNS symptoms was significantly increased with opioid analgesic cotreatment and a higher Glasgow Prognostic Score but not with the absolute value of plasma pregabalin concentrations, eGFR, or other clinical laboratory data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In patients with cancer, steady-state trough plasma pregabalin concentrations were altered with renal function, systemic inflammation, and opioid analgesic cotreatment. However, a higher incidence of CNS symptoms observed in patients with cancer on pregabalin was more related to cachexia and opioid analgesic cotreatment than to altered pregabalin concentrations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000634","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T11:19:47Z","timestamp":1555154387000},"page":"591-597","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Cachexia and Opioid Analgesic Cotreatment on Pregabalin Pharmacokinetics and Central Nervous System Symptoms in Cancer Patients"],"prefix":"10.1097","volume":"41","author":[{"given":"Nozomi","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4088\/JCP.v65n0801","article-title":"Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators","volume":"65","author":"Stahl","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0091270009352087","article-title":"Clinical pharmacokinetics of pregabalin in healthy volunteers","volume":"50","author":"Bockbrader","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R3-20230814","first-page":"303","article-title":"Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin","volume":"8","author":"Parsons","year":"2015","journal-title":"J Pain Res."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/papr.12146","article-title":"A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain","volume":"15","author":"Freynhagen","year":"2015","journal-title":"Pain Pract."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0091270003251119","article-title":"Pharmacokinetics of pregabalin in subjects with various degrees of renal function","volume":"43","author":"Randinitis","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/bja\/aev363","article-title":"Pregabalin reduces postoperative opioid consumption and pain for 1 week after hospital discharge, but does not affect function at 6 weeks or 3 months after total hip arthroplasty","volume":"115","author":"Clarke","year":"2015","journal-title":"Br J Anaesth."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"e6982","DOI":"10.1097\/MD.0000000000006982","article-title":"Pregabalin can decrease acute pain and morphine consumption in laparoscopic cholecystectomy patients: a meta-analysis of randomized controlled trials","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"R9-20230814","first-page":"E547","article-title":"Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases","volume":"16","author":"Nishihara","year":"2013","journal-title":"Pain Physician."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1111\/ajco.12822","article-title":"Efficacy and safety of oxycodone\/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea","volume":"14","author":"Kim","year":"2018","journal-title":"Asia Pac J Clin Oncol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/AJP.0b013e318247809a","article-title":"The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients","volume":"29","author":"Mercadante","year":"2013","journal-title":"Clin J Pain."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/00325481.2017.1384691","article-title":"Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia","volume":"129","author":"Arnold","year":"2017","journal-title":"Postgrad Med."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","article-title":"Cancer cachexia, mechanism and treatment","volume":"7","author":"Aoyagi","year":"2015","journal-title":"World J Gastrointest Oncol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcsm.12012","article-title":"Influence of cancer cachexia on drug liver metabolism and renal elimination in rats","volume":"6","author":"Cvan Trobec","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"e79603","DOI":"10.1371\/journal.pone.0079603","article-title":"Pharmacokinetics of drugs in cachectic patients: a systematic review","volume":"8","author":"Trobec","year":"2013","journal-title":"PLoS One."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-012-1266-x","article-title":"Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients","volume":"68","author":"Naito","year":"2012","journal-title":"Eur J Clin Pharmacol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jcph.112","article-title":"Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients","volume":"53","author":"Naito","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jpainsymman.2017.01.010","article-title":"Management of cancer cachexia and guidelines implementation in a comprehensive cancer center: a physician-led cancer nutrition program adapted to the practices of a country","volume":"54","author":"Senesse","year":"2017","journal-title":"J Pain Symptom Manage."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0000000000000325","article-title":"A validated fluorometric method for the rapid determination of pregabalin in human plasma applied to patients with pain","volume":"38","author":"Yoshikawa","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis."},{"key":"R22-20230814","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2125.2011.03932.x","article-title":"Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy","volume":"72","author":"Shoji","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/08860220701810539","article-title":"Serum CRP levels in pre-dialysis patients","volume":"30","author":"Razeghi","year":"2008","journal-title":"Ren Fail."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1213\/00000539-200007000-00035","article-title":"Gabapentin enhances the analgesic effect of morphine in healthy volunteers","volume":"91","author":"Eckhardt","year":"2000","journal-title":"Anesth Analg."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ejp.728","article-title":"Pregabalin enhances the antinociceptive effect of oxycodone and morphine in thermal models of nociception in the rat without any pharmacokinetic interactions","volume":"20","author":"Jokinen","year":"2016","journal-title":"Eur J Pain."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1124\/dmd.106.012112","article-title":"Mechanism of the regulation of organic cation\/carnitine transporter 1 (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines","volume":"35","author":"Maeda","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/jpet.115.223891","article-title":"Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice","volume":"354","author":"Akamine","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.clpt.6100271","article-title":"Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin","volume":"83","author":"Urban","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1532-5415.2010.02920.x","article-title":"Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis","volume":"58","author":"Papaleontiou","year":"2010","journal-title":"J Am Geriatr Soc."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jpsychores.2006.11.013","article-title":"Cytokines and acute phase response in delirium","volume":"62","author":"de Rooij","year":"2007","journal-title":"J Psychosom Res."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3940(98)00060-3","article-title":"Experimental acute pancreatitis results in increased blood-brain barrier permeability in the rat: a potential role for tumor necrosis factor and interleukin 6","volume":"242","author":"Farkas","year":"1998","journal-title":"Neurosci Lett."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav Immun."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00228-016-2116-z","article-title":"Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients","volume":"72","author":"Sato","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00228-018-2527-0","article-title":"Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients","volume":"74","author":"Tanaka","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1007074420772","article-title":"Inflammatory mediators and modulation of blood-brain barrier permeability","volume":"20","author":"Abbott","year":"2000","journal-title":"Cell Mol Neurobiol."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:22:04Z","timestamp":1692051724000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000634","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}